Total Voting Rights

RNS Number : 2232U

MaxCyte, Inc.

01 April 2021

 

MaxCyte, Inc.

("MaxCyte" or the "Company")

Total Voting Rights

Gaithersburg, Maryland - 1 April 2021:   MaxCyte (LSE: MXCT, MXCL, MXCN), the global cell-based medicines and life sciences company, announces that pursuant to its block admission facility, details of which were announced on 2 May 2017, it has recently issued 125,377 shares of common stock, $0.01 par, of the Company ("Common Stock") in satisfaction of the exercise of share options.

The new Common Stock will rank pari passu with the existing shares of common stock of the Company. The total issued stock capital of the Company following the recent issue of the new Common Stock is 84,684,623 shares of Common Stock. Shareholders in the Company may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the stock capital of the Company.

The number of unrestricted shares of Common Stock trading under the symbol 'MXCT' is 74,454,534 ; the number of restricted shares of Common Stock trading under the symbol 'MXCL' is  9,900,089 a nd the number of restricted shares of Common Stock trading under the symbol 'MXCN' will be 330,000.    

For further information, please contact:

MaxCyte Inc. Doug Doerfler, Chief Executive Officer Ron Holtz, Chief Accounting Officer [phone] Nominated Adviser and Joint Corporate Broker Panmure Gordon Emma Earl Freddy Crossley Corporate Broking Rupert Dearden [phone] Joint Corporate Broker Numis Securities Limited James Black Duncan Monteith [phone] Joint Corporate Broker Stifel Nicolaus Europe Limited Healthcare Investment Banking Nicholas Moore / Ben Maddison / Samira Essebiyea Corporate Broking Nick Adams     [phone]

About MaxCyte

MaxCyte is a world-leading provider of cell-engineering platform technologies that drives the next‐generation of cell and gene-editing therapies. The Company's technology, which is designed to make a meaningful difference for patients, is deployed by leading drug developers worldwide, including all of the top ten global biopharmaceutical companies. MaxCyte licenses have been granted for more than 140 cell therapy programs, with more than 100 licensed for clinical use, and the Company has now entered into 12 clinical/commercial license partnerships with leading cell therapy and gene editing developers. MaxCyte was founded in 1998 and is headquartered in Gaithersburg, Maryland, US.   For more information, visit www.maxcyte.com .

 

END

 

 

TVRDKDBNDBKBNNN